Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:3:31-8.
doi: 10.2147/PROM.S29443. Epub 2012 Jul 11.

Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys

Nobutaka Hattori  1 , Kenichi Fujimoto, Tomoyoshi Kondo, Miho Murata, Mark Stacy
Affiliations

Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys

Nobutaka Hattori et al. Patient Relat Outcome Meas. 2012.

Abstract

Background: Despite evidence suggesting that patient attitudes towards therapy may influence treatment outcomes, the impact of these factors on treatment for Parkinson's disease is poorly understood. These two surveys, based in Japan and the US, investigated the attitudes of patients towards antiparkinsonian medications, the complications of these therapies, and how these differ across geographies.

Methods: The US PRELUDE survey collected data from May 13 to May 20, 2003, from 300 interviews with patients with Parkinson's disease from the National Parkinson Foundation. The Japanese survey was carried out from June to December 2008 in a stepwise manner using questionnaires (n = 3548) followed by interviews with those who had consented to participate in the questionnaire (n = 407). Both surveys assessed the attitudes of patients towards therapies for Parkinson's disease and associated complications.

Results: Dyskinesia was not a major challenge of therapy for Parkinson's disease, and wearing-off caused greater concern in the US, while hallucinations had a greater emphasis in Japan. Patients who had previously experienced dyskinesia were less concerned about this side effect than those who had not. Although pill burden was thought to be a concern in the US, Japanese patients did not indicate that pill burden would limit their drug intake. There were also discrepancies between the perspectives and concerns of patients and those of their treating physicians.

Conclusion: Recognizing patient perspectives regarding therapies for Parkinson's disease and associated complications, as well as certain cultural influences, is important in the management of parkinsonian symptoms. Acknowledging these concerns may improve the standard of care in patients with Parkinson's disease. In addition, improved patient education and effective patient-physician communication in both countries may improve compliance and treatment outcomes in patients with the disease.

Keywords: Parkinson’s disease; dyskinesia; hallucinations; patient concerns; wearing-off.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage of patients in the US survey reporting dyskinesias or wearing-off as the greatest challenge of therapy.
Figure 2
Figure 2
Percentage of patients in the Japanese survey who preferred to avoid adverse events compared with those who preferred relief from bradykinesia. Note: Hoehn and Yahr measurements were taken during off periods. Abbreviation: AE, adverse effect.
Figure 3
Figure 3
Adverse effects of antiparkinsonian medication that concerned patients in the Japanese survey. Note: Patients who did not include a specific response were excluded from this analysis.
See this image and copyright information in PMC

References

    1. Stewart MA. Effective physician-patient communication and health outcomes: a review. Can Med Assoc J. 1995;152(9):1423–1433. - PMC - PubMed
    1. Shortus T, Rose V, Comino E, Zwar N. Patients’ views on chronic illness and its care in general practice. Aust Fam Physician. 2005;34(5):397–399. - PubMed
    1. Osman LM, Hyland ME. Patient needs and medication styles in COPD. Eur Respir Rev. 2005;14(96):89–92.
    1. Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry. 2001;158(3):479–481. - PubMed
    1. Poewe W, Antonini A, Zijlmans JCM, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229–238. - PMC - PubMed